Navigation Links
3SBio Inc. Enters Into Merger Agreement For "Going Private" Transaction
Date:2/8/2013

in the solicitation of proxies will be set forth in the proxy statement and Schedule 13E-3 transaction statement relating to the proposed merger when it is filed with the SEC.  Additional information regarding the interests of such potential participants will be included in the proxy statement and Schedule 13E-3 transaction statement and the other relevant documents filed with the SEC when they become available.

This announcement is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that may be made with the SEC should the proposed merger proceed.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

Safe Harbor Statement

Certain statements contained in this announcement may be viewed as "forward-looking statements" within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995, which may be identified by terminology such as "intend","expect,""will" or "would", "may" or "might".  Such forward-looking statements involve known and unknown risks, uncertainties and other f
'/>"/>

SOURCE 3SBio Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. 3SBio Inc. to Present at the UBS Greater China Conference 2012
2. 3SBio Inc. Files Annual Report on Form 20-F for Fiscal Year 2011
3. 3SBio Inc. Announces Unaudited First Quarter 2012 Results
4. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
5. Two Top Biological Imaging Centers Offer Powerful Free Online Tool to Researchers, Educators, and Public
6. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
7. Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
8. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
9. Top 10 “Best Children’s Hospitals” Include 3 Pediatric Centers Offering SynCardia Total Artificial Heart
10. Centers for Medicare & Medicaid Services Win 2012 National Cybersecurity Innovation Award
11. Nu Skin Enterprises Enters Into Agreement To Acquire NOX Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... company focused on the development of autologous cell ... the International Society for Cellular Therapy (ISCT) on ... currently in a Phase 1/2 clinical trial.  The ... from 5:30 PM to 7:00 PM local time, ...
(Date:5/20/2015)... May 20, 2015 Veracyte, Inc ... data demonstrating the ability of the company,s molecular ... from other interstitial lung diseases (ILDs) using samples ... potential to help thousands of patients avoid invasive, ... IPF diagnosis – a frequent challenge for physicians ...
(Date:5/20/2015)... May 19, 2015 Research and Markets ... "Global Cell Therapy Market Outlook 2020 " ... therapy in tissue and regenerative medicine is expected to ... options which could help in the growth of deregulated ... but they are unable to form new tissue or ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... 16, 2010) In one of only two studies of ... of Medicine and the Sackler School of Graduate Biomedical Sciences ... onset of some forms of eye disease and preserve vision. ... retina and found that treated mice temporarily retained more eyesight ...
... quarter 2010 revenue rose 43% year-over-year to $47.5 million,-- Second quarter 2010 net ... China BCT Reports Strong Second Quarter 2010 Results -- LIUZHOU CITY, ... ... if ...
... along with Indiana University, are excited to announce ... in the Light Microscopy Imaging Center in Bloomington, ... three dimensional, super-resolution microscopy system that more than ... This super-resolution capability is especially important to cell ...
Cached Biology Technology:Breakthrough gene therapy prevents retinal degeneration 2China BCT Reports Strong Second Quarter 2010 Results 2China BCT Reports Strong Second Quarter 2010 Results 3China BCT Reports Strong Second Quarter 2010 Results 4China BCT Reports Strong Second Quarter 2010 Results 5China BCT Reports Strong Second Quarter 2010 Results 6China BCT Reports Strong Second Quarter 2010 Results 7China BCT Reports Strong Second Quarter 2010 Results 8China BCT Reports Strong Second Quarter 2010 Results 9China BCT Reports Strong Second Quarter 2010 Results 10China BCT Reports Strong Second Quarter 2010 Results 11China BCT Reports Strong Second Quarter 2010 Results 12China BCT Reports Strong Second Quarter 2010 Results 13China BCT Reports Strong Second Quarter 2010 Results 14China BCT Reports Strong Second Quarter 2010 Results 15Applied Precision Installs New DeltaVision|OMX® Super-Resolution Imaging System in the Light Microscopy Imaging Center at Indiana University 2
(Date:5/21/2015)... According to a new ... Software, Services), by Applications (Surveillance (Airborne, Maritime, Land), ... (Military & Defense & Commercial) - Global Forecast ... is expected to grow from $7252.0 Million in ... Compound Annual Growth Rate (CAGR) of 6.6%. ...
(Date:5/20/2015)... DUBLIN , May 20, 2015 ... Markets ( http://www.researchandmarkets.com/research/h8t4x6/5year ) has announced the ... of the Global Iris Recognition Market" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service analyses ... across the government and commercial sectors, ...
(Date:5/19/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... proteins have been,viewed as the real movers and ... more than a messenger that shuttles information between ... Research,and Massachusetts Institute of Technology have discovered that ... genes--more,than one third of the genome's protein-coding regions. ...
... 29 March 2005, the Ministry of Health has reported a ... and Uige. All these cases had originated in Uige Province. ... Centers for Disease Control and Prevention (CDC), Atlanta, USA. , ... for southern Africa, the Regional Office for Africa (AFRO) and ...
... York University biologists have uncovered how the innate immune ... The findings, published as the cover study in the ... fight the virus at multiple stages--by preventing the formation ... release, which could infect other cells in the brain. ...
Cached Biology News:NYU researchers simulate molecular biological clock 2NYU Study Reveals How Brain's Immune System Fights Viral Encephalitis 2